terbutaline ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
bronchodilators, phenethylamine derivatives 2598 23031-25-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • terbutaline
  • bricaril
  • terbutalin
  • brican
  • terbutaline sulfate
  • terbutaline hemisulfate
A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.
  • Molecular weight: 225.29
  • Formula: C12H19NO3
  • CLOGP: 0.48
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 4
  • TPSA: 72.72
  • ALOGS: -1.59
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 mg Inhal.aerosol
2 mg Inhal.powder
20 mg Inhal.solution
15 mg O
15 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 213 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 56 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.11 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 14 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.75 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 15 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
March 25, 1974 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 165.57 16.67 121 7054 89216 50508733
Dyspnoea 79.87 16.67 212 6963 547396 50050553
Wheezing 78.06 16.67 67 7108 61980 50535969
Lactic acidosis 50.22 16.67 40 7135 33315 50564634
Squamous cell carcinoma of the oral cavity 44.49 16.67 10 7165 295 50597654
Sputum discoloured 41.37 16.67 25 7150 13370 50584579
Allergy to metals 39.24 16.67 10 7165 507 50597442
Acute kidney injury 36.78 16.67 92 7083 227966 50369983
Iodine allergy 36.22 16.67 10 7165 691 50597258
Shock haemorrhagic 34.96 16.67 19 7156 8325 50589624
Hyperlactacidaemia 34.54 16.67 13 7162 2420 50595529
Sleep disorder due to a general medical condition 34.30 16.67 18 7157 7353 50590596
Forced expiratory volume decreased 33.36 16.67 15 7160 4379 50593570
Obstructive airways disorder 33.03 16.67 23 7152 15629 50582320
Nasal discharge discolouration 32.53 16.67 11 7164 1503 50596446
Tremor 32.06 16.67 58 7117 114845 50483104
Middle insomnia 31.89 16.67 19 7156 9902 50588047
Exposure during pregnancy 31.15 16.67 59 7116 120956 50476993
Full blood count abnormal 28.85 16.67 25 7150 23363 50574586
Hepatocellular injury 28.56 16.67 26 7149 25921 50572028
Bronchospasm 27.15 16.67 20 7155 14834 50583115
Rubber sensitivity 26.90 16.67 10 7165 1799 50596150
Lung diffusion disorder 26.34 16.67 5 7170 62 50597887
Folate deficiency 26.14 16.67 10 7165 1945 50596004
Cholestasis 25.15 16.67 24 7151 25377 50572572
Cough 24.95 16.67 83 7092 241181 50356768
Heart rate increased 24.14 16.67 41 7134 77209 50520740
Post viral fatigue syndrome 23.70 16.67 6 7169 296 50597653
Eosinophilic granulomatosis with polyangiitis 22.61 16.67 9 7166 1946 50596003
Productive cough 22.06 16.67 32 7143 52662 50545287
Haematoma 21.48 16.67 24 7151 30486 50567463
Pleural rub 21.19 16.67 4 7171 48 50597901
Eosinophilia 21.13 16.67 19 7156 18633 50579316
Exposure to allergen 21.04 16.67 5 7170 189 50597760
Phlebectomy 20.69 16.67 4 7171 55 50597894
Asthmatic crisis 20.60 16.67 8 7167 1620 50596329
Spirometry abnormal 20.58 16.67 5 7170 208 50597741
Premature separation of placenta 20.36 16.67 8 7167 1670 50596279
Forced expiratory volume abnormal 19.79 16.67 4 7171 70 50597879
Polyp 18.79 16.67 11 7164 5551 50592398
Foetal exposure during pregnancy 18.37 16.67 21 7154 27338 50570611
Smoke sensitivity 18.22 16.67 5 7170 338 50597611
Tachycardia 17.91 16.67 42 7133 99721 50498228
Hyperkinesia 17.89 16.67 7 7168 1445 50596504
Respiratory rate increased 17.87 16.67 14 7161 11371 50586578
Food allergy 17.27 16.67 12 7163 8125 50589824
Eosinophil count abnormal 16.78 16.67 5 7170 454 50597495
Seasonal allergy 16.72 16.67 15 7160 14661 50583288

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 139.56 18.68 78 4432 33771 29536246
Wheezing 79.09 18.68 54 4456 33186 29536831
Dyspnoea 53.29 18.68 138 4372 326594 29243423
Forced expiratory volume decreased 49.73 18.68 18 4492 2795 29567222
Chest discomfort 49.61 18.68 47 4463 45936 29524081
Hyperkaliuria 48.10 18.68 9 4501 95 29569922
Cholestasis 46.24 18.68 34 4476 23428 29546589
Wolff-Parkinson-White syndrome 42.00 18.68 9 4501 196 29569821
Exposure during pregnancy 41.51 18.68 22 4488 8532 29561485
Agranulocytosis 39.00 18.68 29 4481 20311 29549706
Obstructive airways disorder 36.32 18.68 22 4488 10994 29559023
Bronchospasm 33.78 18.68 20 4490 9589 29560428
Blood immunoglobulin E increased 32.70 18.68 12 4498 1935 29568082
Gastrointestinal mucosal necrosis 32.30 18.68 7 4503 161 29569856
Nasal disorder 32.22 18.68 11 4499 1438 29568579
Placental transfusion syndrome 28.38 18.68 4 4506 4 29570013
Meralgia paraesthetica 27.10 18.68 6 4504 153 29569864
Penile erythema 26.63 18.68 6 4504 166 29569851
Unmasking of previously unidentified disease 26.39 18.68 8 4502 715 29569302
Bronchospasm paradoxical 26.37 18.68 5 4505 57 29569960
Rhinitis 25.21 18.68 13 4497 4765 29565252
Nasal inflammation 24.76 18.68 6 4504 229 29569788
Foetal distress syndrome 23.85 18.68 8 4502 991 29569026
Premature baby 23.21 18.68 20 4490 17260 29552757
Middle insomnia 23.04 18.68 13 4497 5695 29564322
Heart rate increased 22.99 18.68 29 4481 38909 29531108
Respiratory distress 22.36 18.68 26 4484 32080 29537937
Prothrombin time ratio decreased 22.24 18.68 6 4504 353 29569664
Cyanosis 21.44 18.68 16 4494 11251 29558766
Stillbirth 21.11 18.68 5 4505 173 29569844
Cough 20.95 18.68 54 4456 126673 29443344
Ductus arteriosus premature closure 19.86 18.68 5 4505 224 29569793
Interstitial lung disease 19.48 18.68 33 4477 57685 29512332

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 229.59 15.79 162 10707 95063 64392800
Wheezing 129.94 15.79 108 10761 80471 64407392
Dyspnoea 110.93 15.79 317 10552 718357 63769506
Forced expiratory volume decreased 75.43 15.79 32 10837 6835 64481028
Cholestasis 67.85 15.79 58 10811 44814 64443049
Bronchospasm 57.06 15.79 39 10830 21643 64466220
Obstructive airways disorder 57.01 15.79 40 10829 23145 64464718
Lactic acidosis 55.91 15.79 60 10809 61350 64426513
Middle insomnia 51 15.79 30 10839 12847 64475016
Chest discomfort 46.84 15.79 76 10793 116030 64371833
Shock haemorrhagic 46.08 15.79 31 10838 16760 64471103
Heart rate increased 45.94 15.79 69 10800 98606 64389257
Cough 44.97 15.79 132 10737 302016 64185847
Sputum discoloured 44.35 15.79 31 10838 17825 64470038
Hyperkaliuria 42.52 15.79 9 10860 166 64487697
Wolff-Parkinson-White syndrome 38.84 15.79 9 10860 255 64487608
Squamous cell carcinoma of the oral cavity 38.45 15.79 10 10859 461 64487402
Bronchospasm paradoxical 38.14 15.79 8 10861 141 64487722
Productive cough 35.22 15.79 52 10817 73151 64414712
Hyperlactacidaemia 32.44 15.79 16 10853 4828 64483035
Hepatocellular injury 32.33 15.79 39 10830 45196 64442667
Full blood count abnormal 30.52 15.79 31 10838 29726 64458137
Gastrointestinal mucosal necrosis 30.35 15.79 7 10862 194 64487669
Eosinophilic granulomatosis with polyangiitis 30.23 15.79 13 10856 2869 64484994
Acute kidney injury 29.93 15.79 152 10717 449088 64038775
Small intestinal haemorrhage 29.72 15.79 14 10855 3819 64484044
Blood immunoglobulin E increased 29.68 15.79 14 10855 3830 64484033
Tremor 29.30 15.79 72 10797 148158 64339705
Agranulocytosis 29.04 15.79 34 10835 38195 64449668
Haematoma 28.46 15.79 37 10832 46213 64441650
Nasal disorder 26.97 15.79 12 10857 2872 64484991
Penile erythema 26.89 15.79 6 10863 143 64487720
Respiratory distress 26.37 15.79 38 10831 52293 64435570
Nasal discharge discolouration 25.51 15.79 10 10859 1744 64486119
Sleep disorder due to a general medical condition 24.52 15.79 16 10853 8218 64479645
Bronchitis 23.84 15.79 55 10814 108688 64379175
Death 23.61 15.79 28 10841 482677 64005186
Lung disorder 23.46 15.79 39 10830 60661 64427202
Meralgia paraesthetica 23.10 15.79 6 10863 275 64487588
Post viral fatigue syndrome 22.63 15.79 6 10863 298 64487565
Lung diffusion disorder 22.53 15.79 5 10864 116 64487747
Folate deficiency 21.14 15.79 10 10859 2753 64485110
Pleural rub 20.91 15.79 4 10865 43 64487820
Rhinitis 20.66 15.79 16 10853 10749 64477114
Respiratory rate increased 20.46 15.79 20 10849 18311 64469552
Sinus tachycardia 20.19 15.79 26 10843 32162 64455701
Exposure to allergen 20.11 15.79 5 10864 192 64487671
Smoke sensitivity 19.79 15.79 6 10863 485 64487378
Drug intolerance 19.44 15.79 4 10865 187988 64299875
Unmasking of previously unidentified disease 19.17 15.79 8 10861 1639 64486224
Asthmatic crisis 18.68 15.79 8 10861 1748 64486115
Nasal inflammation 18.56 15.79 6 10863 598 64487265
Eosinophilia 18.23 15.79 27 10842 38049 64449814
Systolic hypertension 18.04 15.79 6 10863 654 64487209
Forced expiratory volume abnormal 17.86 15.79 4 10865 97 64487766
Polyp 17.54 15.79 12 10857 6661 64481202
Prothrombin time ratio decreased 17.11 15.79 6 10863 767 64487096
Dermatitis bullous 17.03 15.79 15 10854 12039 64475824
Blood pressure increased 16.42 15.79 65 10804 172487 64315376
Accelerated idioventricular rhythm 16.20 15.79 4 10865 149 64487714

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R03AC03 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Selective beta-2-adrenoreceptor agonists
ATC R03CC03 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS FOR SYSTEMIC USE
Selective beta-2-adrenoreceptor agonists
ATC R03CC53 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS FOR SYSTEMIC USE
Selective beta-2-adrenoreceptor agonists
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058666 Adrenergic beta-2 Receptor Agonists
MeSH PA D000318 Adrenergic beta-Agonists
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D012102 Reproductive Control Agents
MeSH PA D019141 Respiratory System Agents
MeSH PA D013566 Sympathomimetics
MeSH PA D015149 Tocolytic Agents
CHEBI has role CHEBI:35522 beta-adrenergic agonists
CHEBI has role CHEBI:35523 bronchodilator
CHEBI has role CHEBI:35524 sympathomimetic
CHEBI has role CHEBI:35526 antidiabetic
CHEBI has role CHEBI:38462 acetylcholinesterase inhibitors
CHEBI has role CHEBI:49167 anti-asthmatic drugs
CHEBI has role CHEBI:66993 tocolytic drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Bronchitis indication 32398004 DOID:6132
Tear film insufficiency indication 46152009
Pulmonary emphysema indication 87433001
Asthma indication 195967001 DOID:2841
Skin irritation indication 367466007
Asthma management indication 406162001
Itching of skin indication 418363000
Acute exacerbation of asthma indication 708038006
Chronic Obstructive Pulmonary Disease with Bronchospasms indication
Minor Skin Wound Pain indication
Bronchospasm Prevention indication
Premature labor off-label use 6383007
Bronchiectasis off-label use 12295008 DOID:9563
Keratoconjunctivitis sicca off-label use 302896008 DOID:12895
Pulmonary edema contraindication 19242006 DOID:11396
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Hypokalemia contraindication 43339004
Conduction disorder of the heart contraindication 44808001
Ketoacidosis contraindication 56051008
Diabetes mellitus contraindication 73211009 DOID:9351
Compression of umbilical cord contraindication 79222000
Hyperglycemia contraindication 80394007 DOID:4195
Decreased respiratory function contraindication 80954004
Epilepsy contraindication 84757009 DOID:1826
Open wound contraindication 125643001
Seizure disorder contraindication 128613002
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Myocardial ischemia contraindication 414795007 DOID:3393
Placental abruption contraindication 415105001
Denuded skin contraindication 418242004




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.48 acidic
pKa2 11.49 acidic
pKa3 12.74 acidic
pKa4 8.66 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR AGONIST Ki 5.60 WOMBAT-PK CHEMBL
Beta-2 adrenergic receptor GPCR Kd 5.40 CHEMBL

External reference:

IDSource
4019941 VUID
N0000148026 NUI
D00688 KEGG_DRUG
23031-32-5 SECONDARY_CAS_RN
4018396 VANDF
4019941 VANDF
C0039542 UMLSCUI
CHEBI:9449 CHEBI
CHEMBL1760 ChEMBL_ID
DB00871 DRUGBANK_ID
CHEMBL1315867 ChEMBL_ID
CHEMBL1160544 ChEMBL_ID
D013726 MESH_DESCRIPTOR_UI
5403 PUBCHEM_CID
2616 INN_ID
560 IUPHAR_LIGAND_ID
N8ONU3L3PG UNII
10368 RXNORM
41721 MMSL
5548 MMSL
d00752 MMSL
001812 NDDF
004731 NDDF
24583009 SNOMEDCT_US
372745006 SNOMEDCT_US
45311002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TERBUTALINE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 0115-2611 TABLET 2.50 mg ORAL ANDA 23 sections
TERBUTALINE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 0115-2622 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9375 INJECTION 1 mg SUBCUTANEOUS ANDA 22 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9746 INJECTION 1 mg SUBCUTANEOUS ANDA 22 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9746 INJECTION 1 mg SUBCUTANEOUS ANDA 22 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0404-9962 INJECTION, SOLUTION 1 mg SUBCUTANEOUS ANDA 11 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0527-1311 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0527-1318 TABLET 2.50 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 10135-579 TABLET 2.50 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 10135-580 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 10271-101 INJECTION 1 mg SUBCUTANEOUS ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 17478-933 INJECTION 1 mg SUBCUTANEOUS ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 21695-121 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 21695-122 TABLET 2.50 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 24979-132 TABLET 2.50 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 24979-133 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 52584-665 INJECTION, SOLUTION 1 mg SUBCUTANEOUS ANDA 11 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 53808-0312 TABLET 2.50 mg ORAL ANDA 22 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 62559-721 TABLET 2.50 mg ORAL NDA authorized generic 22 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 62559-722 TABLET 5 mg ORAL NDA authorized generic 22 sections
Terbutaline Sulfate Human Prescription Drug Label 1 63323-665 INJECTION, SOLUTION 1 mg SUBCUTANEOUS ANDA 13 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 67296-1053 TABLET 2.50 mg ORAL ANDA 13 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 71205-938 TABLET 2.50 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 71205-938 TABLET 2.50 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 71205-939 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 71205-939 TABLET 5 mg ORAL ANDA 23 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 71872-7080 INJECTION 1 mg SUBCUTANEOUS ANDA 22 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 71872-7130 INJECTION, SOLUTION 1 mg SUBCUTANEOUS ANDA 24 sections
Terbutaline Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 72843-101 INJECTION 1 mg SUBCUTANEOUS ANDA 23 sections